Acta Neuropathologica, 27 April, 2026, DOI：https://doi.org/10.1007/s00401-026-03023-4
A novel BEND2 monoclonal antibody enables highly specific immunohistochemical diagnosis of BEND2-fusion astroblastomas
Qianqian Sun, Yixing Shi, Leiming Wang, Lin Bai, Wanming Hu, Yuqiao Xu, Yueshan Piao, Xueling Qi, Jiang Liu, Hongzhi Guan, Wei Shi & Yang Yu
Abstract
Astroblastoma is a rare CNS tumor characterized by recurrent gene fusions, most commonly MN1::BEND2, less frequent fusion partners include MN1::CXXC5, EWSR1::BEND2, MAMLD1::BEND2 and TCF3::BEND2. Molecular techniques such as next-generation sequencing and DNA methylation profiling are diagnostic gold standards, yet high costs and long turnaround times often limit their use in routine practice. MN1 immunohistochemistry (IHC) has been evaluated as a surrogate marker. However, its diagnostic utility is limited by a lack of specificity because MN1 is also expressed in various non-neoplastic brain tissues and other CNS tumor types. Thus, diagnosis often relies on subjective interpretation of staining intensity rather than a clear presence/absence pattern of MN1 expression, reducing reproducibility in daily diagnostics.
文章链接：https://link.springer.com/article/10.1007/s00401-026-03023-4
附件下载：